It still feels as if the use of cell therapy is a fresh innovation, but inertia is the enemy of progress, and next-gen approaches are already here.
One biotech among a growing pack is the newly uncloaked Clade Therapeutics, which has brought in an impressive $87 million initial funding round led by Syncona with help from LifeSci Venture Partners, Emerson Collective and Bristol Myers Squibb.
